For years, the prevailing wisdom in oncology was that cancer drugs fail because tumors evolve. In this traditional view, a treatment kills the majority of a tumor, but a few cells with the “right” genetic mutations survive, multiply and eventually lead to a relapse. It is a process of natural selection played out in real-time within the human body.
However, latest research suggests that the battle is more dynamic—and more treacherous—than previously understood. Researchers at the Institute for Systems Biology (ISB) have discovered that epigenetic changes allow cancer cells to shift identity and survive drugs almost immediately after treatment begins. Rather than waiting for a lucky mutation to occur, some cancer cells actively reprogram themselves to endure the initial shock of therapy.
The study, published in Nature Communications, reveals that the very act of attacking a tumor can trigger a survival program that pushes a compact fraction of cells into a temporary, drug-tolerant state. This “identity shift” allows the cells to persist under the pressure of medication long before permanent genetic resistance takes hold.
By using high-resolution, time-series multi-omics and computational modeling, the team reconstructed what they call a “molecular movie” of this transition. Instead of simply comparing cells before treatment and after resistance emerged, they tracked the escape process in real time, capturing events that occur within hours and days of the first dose.
A calculated retreat, not a random drift
The researchers focused their investigation on melanoma driven by mutations in the BRAF gene, a frequent target for precision therapies. While these targeted drugs often produce a dramatic initial response, many patients eventually experience a recurrence. The ISB team found that this is not always due to the emergence of new mutations, but rather a reversible shift in the cell’s fundamental identity.
When exposed to BRAF-targeted therapy, melanoma cells do not simply die or wait to mutate. Instead, they undergo a process of dedifferentiation, moving away from their specialized identity as melanoma cells and reverting to a more primitive, therapy-tolerant state. This transition is highly organized, unfolding through two sequential “transcriptional waves” that reorganize how the cell’s genes are expressed.
“We tend to think of drug resistance as something that happens later, after tumors evolve new mutations,” said Wei Wei, PhD, associate professor at ISB and co-senior author of the study. “What we’re seeing here is that the escape process begins almost immediately. Cells actively reprogram themselves to survive the initial shock of therapy.”
Adding a layer of complexity, the researchers observed that this shift is not a simple two-way street. When the drug is removed, the cells do not retrace their steps to their original state. Instead, they return via a different molecular route, retaining a “molecular memory” of the treatment they survived. This suggests that the experience of therapy permanently alters the cell’s future behavior.
The molecular trigger: From stress to survival
The mechanism driving this escape is rooted in the cell’s response to stress. The researchers identified NF-κB, a well-known regulator of cellular survival, as the primary trigger. The process begins when targeted therapy disrupts the cell’s antioxidant defenses, leading to a buildup of reactive oxygen species (ROS). This oxidative stress activates NF-κB, which then initiates a widespread survival program.
Once activated, NF-κB recruits epigenetic enzymes to modify chromatin—the structural packaging of DNA. By changing the chromatin, the cell effectively rewrites which genetic instructions are accessible. One critical target is SOX10, a transcription factor essential for maintaining the identity of a melanocyte (the cell from which melanoma originates). As the “identity genes” like SOX10 are shut down, the cell loses its specialized character and enters the drug-tolerant state.
This distinction between genetic and epigenetic resistance is critical for how clinicians might approach treatment in the future.
| Feature | Genetic Resistance | Epigenetic State Shift |
|---|---|---|
| Timeline | Occurs over weeks or months | Begins within hours or days |
| Mechanism | Permanent DNA mutations | Reversible chromatin remodeling |
| Nature | Random selection of mutants | Coordinated stress response |
| Reversibility | Generally irreversible | Potentially reversible |
Implications for lung and colon cancers
While the primary focus of the study was melanoma, the implications extend far beyond a single cancer type. The ISB team found evidence that similar stress-driven pathways operate in other malignancies, including lung and colon cancers. This suggests that the ability to shift identity in response to therapy may be a broader, fundamental mechanism of resistance across various precision medicines.
This reframes the problem of drug resistance from a genetic puzzle—where doctors search for a specific mutation—to a dynamic “cell-state” problem. If the treatment itself is creating the conditions that allow some cells to survive, then the treatment strategy must change.
“This tells us that resistance isn’t just about which mutations a tumor has,” said Jim Heath, PhD, President of the Institute for Systems Biology and co-senior author of the study. “It’s also about the cell states that treatment itself pushes cancer cells into – and how those states shape future behavior.”
Toward a new strategy in precision oncology
Because the epigenetic shift is reversible and occurs early, it presents a window for intervention. The researchers suggest that rather than waiting for resistance to become permanent, doctors could combine targeted therapies with drugs that block the epigenetic programs downstream of the NF-κB stress response.
By cutting off the escape route at its earliest stage, it may be possible to prevent cancer cells from ever entering the drug-tolerant state, potentially extending the effectiveness of therapies and reducing the likelihood of relapse.
“Resistance may start not only when cancer cells acquire new mutations, but when treatment itself pushes surviving cells into a stronger, more evasive state,” Wei said. “If we can intervene early – at the level of cell-state transitions – we may be able to extend the effectiveness of targeted therapies across multiple cancer types.”
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare professional for diagnosis and treatment options.
The research team continues to investigate how these cell-state transitions vary across different patient populations. The next phase of this work will likely involve testing combination therapies in preclinical models to determine which epigenetic inhibitors are most effective at blocking the survival program.
Do you have questions about the future of precision oncology? Share this story and join the conversation in the comments below.
